M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact BioSpaceMerck will use Protillion Biosciences' tech to design biologic therapies for therapies across undisclosed indications.Read full story pharminent June 17, 2026 (Last updated: June 17, 2026) BioSpace Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. Read full story Post navigation Previous: Moderna builds commercial muscle as new launches loomNext: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026